darzalex
janssen-cilag international n.v. - daratumumab - mielom multiplu - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. în asociere cu bortezomib, talidomida și dexametazona, pentru tratamentul pacienților adulți diagnosticați recent cu mielom multiplu care sunt eligibili pentru transplant autolog de celule stem. în asociere cu lenalidomidă și dexametazonă, sau bortezomib și dexametazonă, pentru tratamentul pacienților adulți cu mielom multiplu care au primit cel puțin un tratament anterior. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. ca monoterapie pentru tratamentul pacienților adulți cu recidivat și refractar mielom multiplu, înainte de a căror terapie a inclus un inhibitor proteazomal și un agent imunomodulator și care au demonstrat progresia bolii în ultima terapie. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
dalvocans 50 mg
pharmathen s.a. - grecia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice
dalvocans 70 mg
pharmathen s.a. - grecia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
tecvayli
janssen-cilag international n.v. - teclistamab - mielom multiplu - agenți antineoplazici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - mielom multiplu - agenți antineoplazici - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - umane igg1 anticorp monoclonal specific uman interleukin-1 alfa - neoplasme colorectale - agenți antineoplazici - tratamentul cancerului colorectal metastatic.
cancidas liofilizat pentru solutie perfuzabila 50 mg
merck sharp&dohme limited - caspofunginum - liofilizat pentru solutie perfuzabila - 50 mg
cancidas liofilizat pentru solutie perfuzabila 70 mg
merck sharp&dohme limited - caspofunginum - liofilizat pentru solutie perfuzabila - 70 mg
idexx schmallenberg ab - schmallenberg virus antibody test kit
mediclim srl, românia - set de diagnostic - reagenti. seturi de diagnostic - bovine, caprine, ovine - detecţia anticorpilor anti virusul schmallenberg şi alte serogrupuri simbu în probe de ser sau plasmă de rumegătoare.